Cargando…
Guselkumab for the Treatment of Palmoplantar Pustulosis: A Japanese Perspective
Palmoplantar pustulosis (PPP) is a chronic inflammatory disorder characterized by sterile pustules predominantly involving the palms and soles. PPP is refractory to various therapies such as topical ointment, oral medicine, and phototherapies. Pustulotic arthro-osteitis (PAO) is a major comorbidity...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8236264/ https://www.ncbi.nlm.nih.gov/pubmed/34188558 http://dx.doi.org/10.2147/CPAA.S266223 |
_version_ | 1783714503308869632 |
---|---|
author | Yamamoto, Toshiyuki |
author_facet | Yamamoto, Toshiyuki |
author_sort | Yamamoto, Toshiyuki |
collection | PubMed |
description | Palmoplantar pustulosis (PPP) is a chronic inflammatory disorder characterized by sterile pustules predominantly involving the palms and soles. PPP is refractory to various therapies such as topical ointment, oral medicine, and phototherapies. Pustulotic arthro-osteitis (PAO) is a major comorbidity of PPP that severely impairs patients’ quality of life. Recently, guselkumab, a monoclonal antibody against IL-23, has been available for the treatment of PPP in Japan. The purpose of the present review is to describe the characteristics of Japanese PPP patients and biologic therapy of PPP/PAO using guselkumab. Most Japanese dermatologists consider PPP as a distinct entity and co-existence of PPP and psoriasis is rare. However, outside Japan, PPP is often considered to be palmoplantar psoriasis, and extra-palmoplantar lesions associated with PPP are regarded as psoriasis. PPP develops or exacerbates either with or without arthralgia, following focal infections, such as tonsillitis, odontogenic infection, and sinusitis. Treatment of focal infection results in dramatic effects on cutaneous lesions as well as joint pain. By contrast, we sometimes see patients whose skin/joint symptoms do not improve after treatment of focal infection, whose focus of infection cannot be identified even in a detailed examination, and/or who refuse tonsillectomy even if strongly recommended. Such cases are considered to be indications of biologics. In this review, clinical features, pathophysiology and guselkumab therapy are discussed. |
format | Online Article Text |
id | pubmed-8236264 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-82362642021-06-28 Guselkumab for the Treatment of Palmoplantar Pustulosis: A Japanese Perspective Yamamoto, Toshiyuki Clin Pharmacol Review Palmoplantar pustulosis (PPP) is a chronic inflammatory disorder characterized by sterile pustules predominantly involving the palms and soles. PPP is refractory to various therapies such as topical ointment, oral medicine, and phototherapies. Pustulotic arthro-osteitis (PAO) is a major comorbidity of PPP that severely impairs patients’ quality of life. Recently, guselkumab, a monoclonal antibody against IL-23, has been available for the treatment of PPP in Japan. The purpose of the present review is to describe the characteristics of Japanese PPP patients and biologic therapy of PPP/PAO using guselkumab. Most Japanese dermatologists consider PPP as a distinct entity and co-existence of PPP and psoriasis is rare. However, outside Japan, PPP is often considered to be palmoplantar psoriasis, and extra-palmoplantar lesions associated with PPP are regarded as psoriasis. PPP develops or exacerbates either with or without arthralgia, following focal infections, such as tonsillitis, odontogenic infection, and sinusitis. Treatment of focal infection results in dramatic effects on cutaneous lesions as well as joint pain. By contrast, we sometimes see patients whose skin/joint symptoms do not improve after treatment of focal infection, whose focus of infection cannot be identified even in a detailed examination, and/or who refuse tonsillectomy even if strongly recommended. Such cases are considered to be indications of biologics. In this review, clinical features, pathophysiology and guselkumab therapy are discussed. Dove 2021-06-23 /pmc/articles/PMC8236264/ /pubmed/34188558 http://dx.doi.org/10.2147/CPAA.S266223 Text en © 2021 Yamamoto. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Review Yamamoto, Toshiyuki Guselkumab for the Treatment of Palmoplantar Pustulosis: A Japanese Perspective |
title | Guselkumab for the Treatment of Palmoplantar Pustulosis: A Japanese Perspective |
title_full | Guselkumab for the Treatment of Palmoplantar Pustulosis: A Japanese Perspective |
title_fullStr | Guselkumab for the Treatment of Palmoplantar Pustulosis: A Japanese Perspective |
title_full_unstemmed | Guselkumab for the Treatment of Palmoplantar Pustulosis: A Japanese Perspective |
title_short | Guselkumab for the Treatment of Palmoplantar Pustulosis: A Japanese Perspective |
title_sort | guselkumab for the treatment of palmoplantar pustulosis: a japanese perspective |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8236264/ https://www.ncbi.nlm.nih.gov/pubmed/34188558 http://dx.doi.org/10.2147/CPAA.S266223 |
work_keys_str_mv | AT yamamototoshiyuki guselkumabforthetreatmentofpalmoplantarpustulosisajapaneseperspective |